News

Eli Lilly (NYSE:LLY) Gains FDA Approval For New Alzheimer's Drug Dosing Schedule
Eli Lilly (NYSE:LLY) recently received FDA approval for a new dosing schedule of Kisunla, aimed at reducing amyloid-related ...
Eli Lilly (LLY) Secures FDA Label Update for Alzheimer’s Disease Treatment
Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the ...
PharmExec5d
FDA Approves Label Update for Eli Lilly’s Kisunla to Reduce ARIA-E Risk in Early Alzheimer Disease Treatment
Approval was based on results from the Phase IIIb TRAILBLAZER-ALZ 6 trial, which showed that Kisunla achieved comparable ...
The Pharma Letter6d
New dosing approved for Lilly’s Kisunla in Alzheimer’s
The US Food and Drug Administration (FDA) has approved a label update with a new recommended titration dosing schedule for ...
BioSpace5d
FDA Rejections: We Read 200 CRLs So You Don’t Have To
A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...
Medical Dialogues6d
Eli Lilly gets USFDA okay for updated Kisunla label with new dosing in early symptomatic Alzheimer's disease
Indianapolis: Eli Lilly and Company has received approval from the U.S. Food and Drug Administration (FDA) for a label update ...
Pharmabiz6d
US FDA approves updated label for Eli Lilly's Kisunla with new dosing in early symptomatic Alzheimer's disease
US FDA approves updated label for Eli Lilly's Kisunla with new dosing in early symptomatic Alzheimer's disease: Indianapolis Thursday, July 10, 2025, 14:00 Hrs [IST] Eli Lilly and ...
US FDA approves gradual dosing for Lilly Alzheimer's drug
The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...
BioSpace4h
FDA Layoffs, 200 Rejection Letters, User Fees and Priority Vouchers, Bad Week for Rare Disease
Around 3,500 FDA employees received termination emails; FDA Commissioner Marty Makary suggests lowering industry user fees ...
Becker's Hospital Review5d
FDA OKs label change for Alzheimer’s drug
The FDA has approved a label update for Eli Lilly’s Kisunla, an Alzheimer’s treatment, by modifying the recommended dosing schedule for adults with early symptomatic Alzheimer’s disease. The update ...
Cantech Letter1d
Health Canada Approves Lilly’s Omvoh® (mirikizumab) for Crohn’s Disease; New Citrate-Free Formulation
Omvoh® is now indicated for both major forms of Inflammatory Bowel Disease (IBD) – ulcerative colitis (UC) and Crohn’s ...
Cognition soars 35% after positive FDA meeting on Alzheimer's asset zervimesine
Cognition Therapeutics surges 35% after a positive FDA meeting for Alzheimer’s drug zervimesine. Read more here.